Article

Hepatitis C Virus Hypervariable Region 1 Variants Presented on Hepatitis B Virus Capsid-Like Particles Induce Cross-Neutralizing Antibodies

Saint Louis University, United States of America
PLoS ONE (Impact Factor: 3.23). 07/2014; 9(7):e102235. DOI: 10.1371/journal.pone.0102235
Source: PubMed

ABSTRACT Hepatitis C virus (HCV) infection is still a serious global health burden. Despite improved therapeutic options, a preventative vaccine would be desirable especially in undeveloped countries. Traditionally, highly conserved epitopes are targets for antibody-based prophylactic vaccines. In HCV-infected patients, however, neutralizing antibodies are primarily directed against hypervariable region I (HVRI) in the envelope protein E2. HVRI is the most variable region of HCV, and this heterogeneity contributes to viral persistence and has thus far prevented the development of an effective HVRI-based vaccine. The primary goal of an antibody-based HCV vaccine should therefore be the induction of cross-reactive HVRI antibodies. In this study we approached this problem by presenting selected cross-reactive HVRI variants in a highly symmetric repeated array on capsid-like particles (CLPs). SplitCore CLPs, a novel particulate antigen presentation system derived from the HBV core protein, were used to deliberately manipulate the orientation of HVRI and therefore enable the presentation of conserved parts of HVRI. These HVRI-CLPs induced high titers of cross-reactive antibodies, including neutralizing antibodies. The combination of only four HVRI CLPs was sufficient to induce antibodies cross-reactive with 81 of 326 (24.8%) naturally occurring HVRI peptides. Most importantly, HVRI CLPs with AS03 as an adjuvant induced antibodies with a 10-fold increase in neutralizing capability. These antibodies were able to neutralize infectious HCVcc isolates and 4 of 19 (21%) patient-derived HCVpp isolates. Taken together, these results demonstrate that the induction of at least partially cross-neutralizing antibodies is possible. This approach might be useful for the development of a prophylactic HCV vaccine and should also be adaptable to other highly variable viruses.

Download full-text

Full-text

Available from: Jörg Timm, Jul 17, 2014
1 Follower
 · 
70 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Virus-like particles (VLPs) comprising viral antigenic proteins capable of inducing protective immunity are attractive candidates as alternative vaccines for a number of reasons (Roy and Noad, 2008; Kushnir et al., 2012). These include their inherent safety profile when produced by recombinant expression technology; since they contain no viral genetic material, they are incapable of accidentally transmitting infection. They can also present a means of producing practicable amounts of material, which is often difficult or impossible to obtain by culturing ...
    Viral Nanotechnology, Edited by Yury Khudyakov, Paul Pumpens, 06/2015: chapter 11: pages 177-186; CRC Press., ISBN: 9781466583528